Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene-Modified Stem Cells for HIV-Associated Lymphoma
NCT02343666Phase 1Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2016
- Primary completion
- Aug 2020
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C46/CCR5/P140K-transduced autologous hematopoietic stem and progenitor cells in human immunodeficiency virus infection (HIV), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Feasibility of collection, Feasibility of infusion of gene modified cells and 6 more. Planned start Aug 2016; status: withdrawn.
02
Drugs
C46/CCR5/P140K-transduced autologous hematopoietic stem and progenitor cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02343666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343666.